Insulin LY2605541 tops glargine for glycemic control in T1DM

[Northerner]

For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 in Diabetes Care.

Julio Rosenstock, M.D., of the Dallas Diabetes and Endocrine Center, and colleagues conducted a randomized, phase 2, open-label, crossover study involving 137 patients with type 1 diabetes who received once-daily basal insulin (LY2605541 or glargine) plus mealtime insulin for eight weeks.

http://medicalxpress.com/news/2013-01-insulin-ly2605541-tops-glargine-glycemic.html

They're going to have to think of a catchier name for it! 🙂

 

[fencesitter]

Yes, the name needs a bit of work ... Might be good for people with night time hypos, but everyone else might find the drawbacks outweigh the benefits? "The rate of nocturnal hypoglycemia was significantly lower with LY2605541, while the incidence of total hypoglycemia was significantly higher. LY2605541 was also associated with more gastrointestinal-related adverse events than insulin glargine (15 versus 4 percent)."

 

[trophywench]

Gosh - who knew Lantus had gastro-intestinal effects? Yup, it was rhetorical, the 4% knew didn't they.....

What g-i effects?